Literature DB >> 14749985

Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil.

Michael C Jendro1, Henning Zeidler, Herbert Rosenthal, Hermann Haller, Anke Schwarz.   

Abstract

Erdheim-Chester disease (ECD) is a rare non-Langerhans' form of histiocytosis with a plethora of different clinical manifestations owing to multiple organ involvement. We report two patients who presented initially with different clinical symptoms. The presenting complaint of the first patient was bone pain, predominantly in the legs, whereas in the other patient the initial symptoms were related to obstruction of both ureters, as in idiopathic retroperitoneal fibrosis. Ultimately, ECD was diagnosed in both patients by the occurrence of both pathognomonic manifestations, the histologic presence of non-Langerhans' histiocytes in bone biopsies, and osteosclerotic lesions of the long bones. Because the extraosseous manifestations progressed and a single application of corticosteroids was ineffective, sequential treatment with vinblastine and mycophenolate mofetil, together with prednisolone, was started. At follow-up respectively 15 and 16 months after the start of treatment a beneficial effect was noted in both patients. These cases illustrate the clinical spectrum of ECD, detail the pathognomonic manifestations of this rare disease, emphasize the need to consider ECD as an uncommon but important differential diagnosis in patients with arthralgias or systemic fibrosis, and give the first evidence for a new treatment option.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14749985     DOI: 10.1007/s10067-003-0801-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  "Coated aorta": a new sign of Erdheim-Chester disease.

Authors:  J Serratrice; B Granel; C De Roux; J F Pellissier; L Swiader; J M Bartoli; P Disdier; P J Weiller
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

2.  Two enlarged kidneys: a manifestation of Erdheim-Chester disease.

Authors:  M André; I Delèvaux; B de Fraissinette; J Ponsonnaille; N Costes Chalret; B Wechsler; J C Piette; O Aumaître
Journal:  Am J Nephrol       Date:  2001 Jul-Aug       Impact factor: 3.754

3.  Cardiac tumor due to Erdheim-Chester disease.

Authors:  P Ammann; B Bösch; S Buchholz; M Genoni; I Laube; B Naegeli
Journal:  Am J Med       Date:  2001-12-01       Impact factor: 4.965

4.  [Cerebral manifestations of Erdheim-Chester disease].

Authors:  C Kujat; B Junk; M Hermes; J Martin; W Dewes
Journal:  Radiologe       Date:  1991-06       Impact factor: 0.635

5.  Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids.

Authors:  W Grotz; I von Zedtwitz; M Andre; P Schollmeyer
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

Review 6.  Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases.

Authors:  C Veyssier-Belot; P Cacoub; D Caparros-Lefebvre; J Wechsler; B Brun; M Remy; B Wallaert; H Petit; A Grimaldi; B Wechsler; P Godeau
Journal:  Medicine (Baltimore)       Date:  1996-05       Impact factor: 1.889

7.  LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.

Authors:  S Ladisch; H Gadner; M Aricò; V Broadbent; N Grois; A Jacobson; D Komp; H S Nicholson
Journal:  Med Pediatr Oncol       Date:  1994

8.  Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease.

Authors:  G Mossetti; D Rendina; F G Numis; P Somma; L Postiglione; V Nunziata
Journal:  Clin Exp Rheumatol       Date:  2003 Mar-Apr       Impact factor: 4.473

Review 9.  Erdheim-Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings.

Authors:  Anu Gupta; Benjamin Kelly; James E McGuigan
Journal:  Am J Med Sci       Date:  2002-08       Impact factor: 2.378

Review 10.  Histiocytes and histiocytosis.

Authors:  M J Cline
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

View more
  6 in total

1.  FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role.

Authors:  Emőke Steňová; Boris Steňo; Pavol Povinec; František Ondriaš; Jana Rampalová
Journal:  Rheumatol Int       Date:  2010-12-07       Impact factor: 2.631

Review 2.  Erdheim-Chester Disease: a comprehensive review of the literature.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Yehuda Shoenfeld
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action.

Authors:  Thitinan Srikulmontree; H Davis Massey; W Neal Roberts
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

Review 5.  Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.

Authors:  Alessandro Broccoli; Vittorio Stefoni; Luca Faccioli; Claudio Agostinelli; Luca Spinardi; Marco Pastore Trossello; Pier Luigi Zinzani
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

6.  Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Anat Kesler; Orna Aizenstein; Iris Eshed; Ronald Jaffe; Yakov Pessach; Ilan Goldberg; Eli Sprecher; Iris Yaish; Alexander Gural; Chezi Ganzel; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2014-12-01       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.